CRISPRclean Advantage Position Jumpcode Genomics’ CRISPRclean technology as a differentiator that removes uninformative sequences to boost sensitivity of NGS assays, enabling faster pathogen detection, infectious disease research, and oncology studies for clients seeking higher-quality sequencing data.

Strategic Partnerships Highlight existing and potential collaborations (BARDA, Element Biosciences, TGen) as proof of credible validation and co-development opportunities, and target similar biotech, clinical labs, and academic institutions that value validated integration with diverse sequencing platforms.

Platform Synergy Leverage compatibility with major sequencing ecosystem players (Illumina, Element AVITI, NGS workflows) to upsell CRISPRclean kits and depletion portfolios to labs adopting or evaluating new sequencing platforms and library prep workflows.

Expanding Clinical Reach Emphasize applicability across clinical services including infectious disease and oncology, and pursue opportunities with contract research organizations and hospital systems seeking improved diagnostic assay sensitivity and faster turnaround using CRISPRclean depletion.

Growth via Education Capitalize on launches of RNA depletion and single-cell kits to drive outreach campaigns, field demonstrations, and case studies that convert researchers into customers by showcasing tangible improvements in signal-to-noise and discovery potential.